EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Characteristics, Progression, and Output of Randomized Platform Trials

Alexandra Griessbach, Christof Manuel Schönenberger, Ala Taji Heravi, Viktoria Gloy, Arnav Agarwal, Tim Jonas Hallenberger, Stefan Schandelmaier, Perrine Janiaud, Alain Amstutz, Manuela Covino, David Mall, Benjamin Speich und 1 weitere

JAMA Network Open · 20.03.2024 · 7 (3) · e243109

DOI: 10.1001/jamanetworkopen.2024.3109 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 20.03.2024. Verfasst von Alexandra Griessbach und 12 weiteren Autor:innen. Beteiligte Einrichtung: CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Swit…. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Platform trials have become increasingly common, and evidence is needed to determine how this trial design is actually applied in current research practice.

Objective

To determine the characteristics, progression, and output of randomized platform trials. Evidence Review In this systematic review of randomized platform trials, Medline, Embase, Scopus, trial registries, gray literature, and preprint servers were searched, and citation tracking was performed in July 2022. Investigators were contacted in February 2023 to confirm data accuracy and to provide updated information on the status of platform trial arms. Randomized platform trials were eligible if they explicitly planned to add or drop arms. Data were extracted in duplicate from protocols, publications, websites, and registry entries. For each platform trial, design features such as the use of a common control arm, use of nonconcurrent control data, statistical framework, adjustment for multiplicity, and use of additional adaptive design features were collected. Progression and output of each platform trial were determined by the recruitment status of individual arms, the number of arms added or dropped, and the availability of results for each intervention arm.

Findings

The search identified 127 randomized platform trials with a total of 823 arms; most trials were conducted in the field of oncology (57 [44.9%]) and COVID-19 (45 [35.4%]). After a more than twofold increase in the initiation of new platform trials at the beginning of the COVID-19 pandemic, the number of platform trials has since declined. Platform trial features were often not reported (not reported: nonconcurrent control, 61 of 127 [48.0%]; multiplicity adjustment for arms, 98 of 127 [77.2%]; statistical framework, 37 of 127 [29.1%]). Adaptive design features were only used by half the studies (63 of 127 [49.6%]). Results were available for 65.2% of closed arms (230 of 353). Premature closure of platform trial arms due to recruitment problems was infrequent (5 of 353 [1.4%]). Conclusions and Relevance This systematic review found that platform trials were initiated most frequently during the COVID-19 pandemic and declined thereafter. The reporting of platform features and the availability of results were insufficient. Premature arm closure for poor recruitment was rare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicHumansCOVID-19Research DesignSARS-CoV-2Adaptive Clinical Trials as Topic

Autor:innen und Institutionen

  • CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.
  • Pragmatic Evidence Lab, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland.

Zitieren

APA

Griessbach, A., Schönenberger, C. M., Taji Heravi, A., Gloy, V., Agarwal, A., Hallenberger, T. J., Schandelmaier, S., Janiaud, P., Amstutz, A., Covino, M., Mall, D., Speich, B., & Briel, M. (2024). Characteristics, Progression, and Output of Randomized Platform Trials. JAMA Network Open, 7(3), e243109. https://doi.org/10.1001/jamanetworkopen.2024.3109

Vancouver

Griessbach A, Schönenberger CM, Taji Heravi A, Gloy V, Agarwal A, Hallenberger TJ, et al. Characteristics, Progression, and Output of Randomized Platform Trials. JAMA Network Open. 2024;7(3):e243109. doi:10.1001/jamanetworkopen.2024.3109

BibTeX
@article{Griessbach2024,
  author = {Griessbach, Alexandra and Schönenberger, Christof Manuel and Taji Heravi, Ala and Gloy, Viktoria and Agarwal, Arnav and Hallenberger, Tim Jonas and Schandelmaier, Stefan and Janiaud, Perrine and Amstutz, Alain and Covino, Manuela and Mall, David and Speich, Benjamin and Briel, Matthias},
  title = {Characteristics, Progression, and Output of Randomized Platform Trials},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {3},
  pages = {e243109},
  doi = {10.1001/jamanetworkopen.2024.3109}
}
Kostenlos starten →